We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Nutriband Inc (NTRB) USD0.001

Sell:$3.85 Buy:$4.95 Change: $0.03 (0.73%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.03 (0.73%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.03 (0.73%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. The Company's lead product is its AVERSA technology, an abuse deterrent technology that can be incorporated into any transdermal patch to deter the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Its first product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an existing generic fentanyl patch with its AVERSA technology to reduce the abuse and misuse of fentanyl patches. It is also focused on the development of additional products utilizing the AVERSA abuse deterrent transdermal technology, which include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, it is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are typically delivered by injection. Its subsidiaries include 4P Therapeutics LLC and Pocono Pharmaceuticals Inc.

Contact details

121 S Orange Ave Ste 1500
United States
+1 (407) 3776695

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$32.00 million
Shares in issue:
7.84 million
United States
US dollar

Key personnel

  • Serguei Melnik
    Chairman of the Board, President, Company Secretary
  • Gareth Sheridan
    Chief Executive Officer, Director
  • Gerald Goodman
    Chief Financial Officer, Chief Accounting Officer
  • Alan Smith
    Chief Operating Officer, President - 4P Therapeutics
  • Patrick Ryan
    Chief Technical Officer
  • Jeff Patrick
    Chief Scientific Officer
  • Larry Dillaha
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.